Evidence map›Paper›PMID 27282398›Full record

ReviewNeuro-oncology2017

Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Chris Jones, Matthias A Karajannis, David T W Jones, Mark W Kieran, Michelle Monje, Suzanne J Baker, Oren J Becher, Yoon-Jae Cho, Nalin Gupta, Cynthia Hawkins and 14 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 237 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/RefractoryJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Intraoperative MRI in pediatric brain tumor surgery: an 18-year single-center experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Chris JonesDivisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Matthias A KarajannisDivision of Pediatric Hematology/Oncology, NYU Langone Medical Center, New York, NY, USA.
David T W JonesDivision of Pediatric Neurooncology, German Cancer Research Centre, Heidelberg, Germany.
Mark W KieranPediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Michelle MonjeDepartment of Neurology & Neurological Sciences, Stanford University, Stanford, California, USA.
Suzanne J BakerDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Oren J BecherDepartments of Pediatrics and Pathology, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA.
Yoon-Jae ChoDepartment of Neurology & Neurological Sciences, Stanford University, Stanford, California, USA.
Nalin GuptaDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Cynthia HawkinsThe Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.
Darren HargraveNeuro-oncology and Experimental Therapeutics, Great Ormond Street Hospital for Children, London, UK.
Daphne A Haas-KoganDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nada JabadoDepartment of Pediatrics, McGill University, Montreal, Canada.
Xiao-Nan LiBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Sabine MuellerDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Theo NicolaidesDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Roger J PackerCenter for Neuroscience and Behavioral Medicine, Children's National Health System, Washington, District of Columbia, USA.
Anders I PerssonDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Joanna J PhillipsDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Erin F SimondsDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
James M StaffordDepartment of Biochemistry, NYU Langone Medical Center, New York, New York, USA.
Yujie TangKey Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Centre, Heidelberg, Germany.
William A WeissDepartments of Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.

Funding

Cancer Research UK 11736Cancer Research UK 13982
6 · The paper itself

Abstract

High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.

Indexed as

Brain NeoplasmsCell Transformation, NeoplasticChildGliomaHumansNeoplasm GradingPrognosisclinical trialsDIPGgenomicsgliomapediatric

Identifiers

PMID27282398
PMCPMC5464243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.